Oral semaglutide, a co-formulation of the human glucagon-like peptide-1 (GLP-1) analogue semaglutide and the absorption enhancer sodium N-[8(2-hydroxybenzoyl)amino]caprylate (SNAC), is the first GLP-1RA developed for oral administration in type 2 diabetes [20, 21]. Here, GCG is linked to type 2 diabetes mellitus.